Lipocine (NASDAQ:LPCN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Lipocine (NASDAQ:LPCN) from a sell rating to a hold rating in a research note published on Sunday.

A number of other research firms also recently issued reports on LPCN. Weiss Ratings restated a “sell (d-)” rating on shares of Lipocine in a research note on Monday, December 29th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective (up from $7.00) on shares of Lipocine in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Lipocine currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Lipocine Trading Up 0.7%

Shares of LPCN opened at $7.36 on Friday. The firm has a fifty day simple moving average of $8.97 and a two-hundred day simple moving average of $5.59. The firm has a market cap of $53.73 million, a PE ratio of -4.37 and a beta of 0.98. Lipocine has a 1-year low of $2.52 and a 1-year high of $12.37.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.12 million.

Institutional Trading of Lipocine

Several institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC lifted its stake in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock valued at $300,000 after buying an additional 1,300 shares in the last quarter. Geode Capital Management LLC increased its stake in Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after buying an additional 1,374 shares in the last quarter. Jane Street Group LLC bought a new stake in Lipocine during the fourth quarter valued at about $85,000. Citadel Advisors LLC bought a new stake in Lipocine during the third quarter valued at about $41,000. Finally, Boothbay Fund Management LLC purchased a new position in shares of Lipocine in the fourth quarter valued at about $441,000. 9.11% of the stock is currently owned by institutional investors.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.